ONCY

Oncolytics Biotech

0.5700 USD
+0.0138
2.48%
At close Apr 28, 4:00 PM EDT
1 day
2.48%
5 days
-5.94%
1 month
-5.00%
3 months
-21.92%
6 months
-53.28%
Year to date
-38.70%
1 year
-47.71%
5 years
-67.43%
10 years
-19.27%
 

About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Employees: 28

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

10% more capital invested

Capital invested by funds: $1.1M [Q3] → $1.21M (+$107K) [Q4]

10% more funds holding

Funds holding: 42 [Q3] → 46 (+4) [Q4]

0.15% more ownership

Funds ownership: 1.55% [Q3] → 1.71% (+0.15%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
426%
upside
Avg. target
$4.33
660%
upside
High target
$5
777%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Maxim Group
Jason McCarthy
16% 1-year accuracy
5 / 32 met price target
426%upside
$3
Buy
Maintained
10 Mar 2025
HC Wainwright & Co.
Patrick Trucchio
23% 1-year accuracy
43 / 187 met price target
777%upside
$5
Buy
Reiterated
10 Mar 2025
RBC Capital
Douglas Miehm
50% 1-year accuracy
12 / 24 met price target
777%upside
$5
Outperform
Maintained
10 Mar 2025

Financial journalist opinion

Based on 3 articles about ONCY published over the past 30 days

Neutral
PRNewsWire
4 days ago
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO and CALGARY, AB , April 24, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options. "Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist," said Thomas Heineman, M.D.
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
Neutral
PRNewsWire
2 weeks ago
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value.
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
Neutral
PRNewsWire
2 weeks ago
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by H.C. Wainwright.
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Neutral
Seeking Alpha
1 month ago
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2024 Results Conference Call March 7, 2025 8:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Wayne Pisano - Chairman of Oncotic's Board of Directors and Interim CEO Tom Heineman - Chief Medical Officer Kirk Look - Chief Financial Officer Christophe Degois - Vice President of Business Development Conference Call Participants Michael Freeman - Raymond James Luis Santos - H.C. Wainwright Operator Good morning, and welcome to Oncolytics Biotech's Fourth Quarter and Full Year 2024 conference call.
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing Cash position of $15.9 million provides runway through critical milestones into third quarter 2025 Management hosting conference call and webcast this morning at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , March 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024.
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
Negative
Zacks Investment Research
1 month ago
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Oncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m.
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential impact across a range of tumors //Republication of press release issued February 18 th 2025 due to news transmission coverage// SAN DIEGO and CALGARY, AB , Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types SAN DIEGO and CALGARY, AB , Feb. 18, 2025 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Neutral
PRNewsWire
2 months ago
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on February 13, 2025 indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company's ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Charts implemented using Lightweight Charts™